• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血浆激肽释放酶裂解人高分子量激肽原的动力学途径中的表面诱导变化。

Surface-induced alterations in the kinetic pathway for cleavage of human high molecular weight kininogen by plasma kallikrein.

作者信息

Tayeh M A, Olson S T, Shore J D

机构信息

Division of Biochemical Research, Henry Ford Hospital, Detroit, Michigan 48202.

出版信息

J Biol Chem. 1994 Jun 10;269(23):16318-25.

PMID:8206938
Abstract

We have studied the cleavage of human high molecular weight kininogen (HK) by plasma kallikrein in the absence and presence of the surfaces, dextran sulfate (DxSO4) and sulfatides. Using a combination of SDS-polyacrylamide gel electrophoresis, Western blotting with polyclonal antibodies that specifically recognize the COOH terminus of the bradykinin moiety, and high pressure liquid chromatography analyses of the cleavage reaction, we have identified two intermediates in the formation of bradykinin from intact kininogen and demonstrated that alternative cleavage pathways are followed in the absence and presence of surfaces. The COOH-terminal bradykinin cleavage occurred first both in the absence and presence of DxSO4, producing a 103-kDa HK intermediate consisting of disulfide-linked heavy and light chains that retained the kinin moiety. In the presence of DxSO4, this was followed exclusively by the NH2-terminal bradykinin cleavage and release of kinin with no apparent change in molecular mass. Subsequently, a slower cleavage of an 8-kDa peptide from the amino terminus of the HK light chain occurred to form a 95-kDa end product. In contrast to this sequential cleavage pattern, NH2-terminal bradykinin and light chain cleavages occurred randomly in the absence of DxSO4, resulting in the production of an additional 95-kDa intermediate that retained bradykinin but had lost the 8-kDa peptide from the HK light chain. Comparison of the relative rates of the three kallikrein cleavages in the absence and presence of DxSO4 indicated that the surface enhanced the rates of both bradykinin cleavages 2-4-fold, but inhibited the light chain cleavage rate approximately 10-fold, thereby accounting for the change from a partially random to a sequential cleavage pattern in the presence of the surface. Steady-state kinetic analysis revealed that DxSO4 enhanced the kcat/KM for bradykinin release by the rate-limiting NH2-terminal bradykinin cleavage by approximately 2-fold due exclusively to an increase in kcat. Sulfatides appeared to produce the same effects on the pattern of HK cleavages as DxSO4. Blocking of the nonactive site, i.e. exosite, interaction between kallikrein and HK with excess prekallikrein or a synthetic peptide containing the region of HK that interacts with the kallikrein exosite significantly reduced the rate of bradykinin release as well as HK cleavages detected by SDS-polyacrylamide gel electrophoresis either in the absence or presence of DxSO4, indicating that the exosite interaction facilitates bradykinin cleavage.

摘要

我们研究了在不存在和存在表面物质硫酸葡聚糖(DxSO4)和硫苷脂的情况下,血浆激肽释放酶对人高分子量激肽原(HK)的裂解作用。通过结合使用十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳、用特异性识别缓激肽部分COOH末端的多克隆抗体进行蛋白质印迹分析以及对裂解反应进行高压液相色谱分析,我们确定了完整激肽原形成缓激肽过程中的两种中间体,并证明在不存在和存在表面物质的情况下遵循不同的裂解途径。在不存在和存在DxSO4的情况下,COOH末端缓激肽裂解均首先发生,产生一种103 kDa的HK中间体,其由保留激肽部分的二硫键连接的重链和轻链组成。在存在DxSO4的情况下,随后仅发生NH2末端缓激肽裂解并释放激肽,分子量无明显变化。随后,从HK轻链的氨基末端缓慢裂解一个8 kDa的肽,形成95 kDa的终产物。与这种顺序裂解模式相反,在不存在DxSO4的情况下,NH2末端缓激肽和轻链裂解随机发生,导致产生另一种95 kDa的中间体,其保留缓激肽但已从HK轻链丢失8 kDa的肽。比较在不存在和存在DxSO4的情况下三种激肽释放酶裂解的相对速率表明,表面物质使两种缓激肽裂解速率提高了2 - 4倍,但使轻链裂解速率降低了约10倍,从而解释了在存在表面物质时从部分随机裂解模式到顺序裂解模式的变化。稳态动力学分析表明,DxSO4仅通过增加催化常数(kcat)使限速的NH2末端缓激肽裂解释放缓激肽的kcat/KM提高了约2倍。硫苷脂似乎对HK裂解模式产生与DxSO4相同的影响。用过量的前激肽释放酶或含有与激肽释放酶外位点相互作用的HK区域的合成肽阻断激肽释放酶与HK之间的非活性位点即外位点相互作用,显著降低了缓激肽释放速率以及在不存在或存在DxSO4的情况下通过十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳检测到的HK裂解速率,表明外位点相互作用促进缓激肽裂解。

相似文献

1
Surface-induced alterations in the kinetic pathway for cleavage of human high molecular weight kininogen by plasma kallikrein.血浆激肽释放酶裂解人高分子量激肽原的动力学途径中的表面诱导变化。
J Biol Chem. 1994 Jun 10;269(23):16318-25.
2
The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain.缓激肽的羧基末端和激肽原轻链的氨基末端构成一个内皮细胞结合域。
J Biol Chem. 1994 Dec 16;269(50):31822-30.
3
Generation of vasoactive peptide bradykinin from human umbilical vein endothelium-bound high molecular weight kininogen by plasma kallikrein.血浆激肽释放酶从人脐静脉内皮细胞结合的高分子量激肽原生成血管活性肽缓激肽。
Blood. 1992 Oct 15;80(8):1980-8.
4
The kinin released from high molecular weight-kininogen is responsible for inflammatory exudation in rats: detection of kinin-free-kininogen in the exudate by immunoblot analysis.从高分子量激肽原释放的激肽可导致大鼠炎症渗出:通过免疫印迹分析检测渗出液中无激肽的激肽原。
Life Sci. 1993;53(22):1691-701. doi: 10.1016/0024-3205(93)90206-i.
5
Studies on porcine high molecular weight kininogen. An improved method for the purification of porcine high molecular weight kininogen and cleavage of the kininogen by the action of porcine plasma kallikrein.猪高分子量激肽原的研究。一种改进的猪高分子量激肽原纯化方法以及猪血浆激肽释放酶作用下激肽原的裂解。
Comp Biochem Physiol B Biochem Mol Biol. 1998 Aug;120(4):647-56. doi: 10.1016/s0305-0491(98)10057-3.
6
High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage.高分子量激肽原通过其重链和轻链与血小板结合,结合后对激肽释放酶裂解的敏感性发生改变。
Blood. 1992 Mar 1;79(5):1233-44.
7
Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor.前激肽释放酶对高分子量激肽原的XII因子非依赖性裂解及C1抑制剂的抑制作用
J Allergy Clin Immunol. 2009 Jul;124(1):143-9. doi: 10.1016/j.jaci.2009.02.006. Epub 2009 Apr 1.
8
Localization of distinct functional domains on prekallikrein for interaction with both high molecular weight kininogen and activated factor XII in a 28-kDa fragment (amino acids 141-371).前激肽释放酶上不同功能结构域的定位,以便与高分子量激肽原和28 kDa片段(氨基酸141 - 371)中的活化因子XII相互作用。
J Biol Chem. 1991 May 5;266(13):8143-8.
9
Comparison of human high molecular weight kininogen digestion by plasma kallikrein and by plasmin. A revised method of purification of high molecular weight kininogen.血浆激肽释放酶和纤溶酶对人高分子量激肽原消化作用的比较。一种改进的高分子量激肽原纯化方法。
J Lab Clin Med. 1987 Apr;109(4):469-79.
10
Cleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1.补体成分:甘露糖结合凝集素相关丝氨酸蛋白酶(MASP)-1 对激肽原的裂解及随后缓激肽的释放。
PLoS One. 2011;6(5):e20036. doi: 10.1371/journal.pone.0020036. Epub 2011 May 23.

引用本文的文献

1
A mechanistic model of in vitro plasma activation to evaluate therapeutic kallikrein-kinin system inhibitors.一种体外等离子体激活的机制模型,用于评估治疗性激肽释放酶-激肽系统抑制剂。
PLoS Comput Biol. 2024 Nov 4;20(11):e1012552. doi: 10.1371/journal.pcbi.1012552. eCollection 2024 Nov.
2
In vitro reconstitution of kallikrein-kinin system and progress curve analysis.体外重建激肽释放酶-激肽系统及进度曲线分析。
Biosci Rep. 2022 Oct 28;42(10). doi: 10.1042/BSR20221081.
3
Cleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1.
补体成分:甘露糖结合凝集素相关丝氨酸蛋白酶(MASP)-1 对激肽原的裂解及随后缓激肽的释放。
PLoS One. 2011;6(5):e20036. doi: 10.1371/journal.pone.0020036. Epub 2011 May 23.
4
Ferritin binds to light chain of human H-kininogen and inhibits kallikrein-mediated bradykinin release.铁蛋白与人H-激肽原轻链结合并抑制激肽释放酶介导的缓激肽释放。
Biochem J. 2002 Jul 1;365(Pt 1):279-86. doi: 10.1042/BJ20011637.
5
Absorption of kininogen from human plasma by Streptococcus pyogenes is followed by the release of bradykinin.化脓性链球菌从人血浆中吸收激肽原后会释放缓激肽。
Biochem J. 1997 Sep 15;326 ( Pt 3)(Pt 3):657-60.